3,241 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Orion Portfolio Solutions LLC
Orion Portfolio Solutions LLC bought a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,241 shares of the medical equipment provider’s stock, valued at approximately $147,000.
A number of other institutional investors and hedge funds have also bought and sold shares of BSX. Allworth Financial LP increased its stake in Boston Scientific by 22.8% in the 4th quarter. Allworth Financial LP now owns 1,345 shares of the medical equipment provider’s stock worth $61,000 after purchasing an additional 250 shares in the last quarter. Contravisory Investment Management Inc. increased its position in shares of Boston Scientific by 17.1% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,796 shares of the medical equipment provider’s stock valued at $81,000 after purchasing an additional 262 shares during the period. Thrivent Financial for Lutherans grew its position in Boston Scientific by 0.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 63,529 shares of the medical equipment provider’s stock valued at $2,873,000 after acquiring an additional 265 shares during the period. Dorsey & Whitney Trust CO LLC grew its position in Boston Scientific by 3.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 8,782 shares of the medical equipment provider’s stock valued at $397,000 after acquiring an additional 269 shares during the period. Finally, Advisor Partners LLC grew its position in Boston Scientific by 0.6% in the fourth quarter. Advisor Partners LLC now owns 44,221 shares of the medical equipment provider’s stock valued at $1,882,000 after acquiring an additional 270 shares during the period. 91.79% of the stock is owned by hedge funds and other institutional investors.
Shares of BSX traded up $1.70 during mid-day trading on Wednesday, reaching $29.92. The company’s stock had a trading volume of 19,681,675 shares, compared to its average volume of 11,092,059. Boston Scientific Co. has a 1-year low of $24.10 and a 1-year high of $46.62. The stock has a market cap of $36.06 billion, a P/E ratio of 8.99, a PEG ratio of 1.48 and a beta of 0.87. The business has a 50-day simple moving average of $37.26 and a two-hundred day simple moving average of $41.19. The company has a current ratio of 0.97, a quick ratio of 0.64 and a debt-to-equity ratio of 0.62.
In related news, CFO Daniel J. Brennan sold 20,463 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $42.03, for a total transaction of $860,059.89. Following the sale, the chief financial officer now owns 250,710 shares of the company’s stock, valued at approximately $10,537,341.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP John Bradley Sorenson sold 7,500 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $42.48, for a total value of $318,600.00. Following the sale, the senior vice president now directly owns 34,073 shares in the company, valued at approximately $1,447,421.04. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,875 shares of company stock valued at $2,709,790. 0.66% of the stock is currently owned by insiders.
A number of analysts have weighed in on BSX shares. Wells Fargo & Co upped their price target on Boston Scientific from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Cowen reissued a “buy” rating and issued a $52.00 price objective on shares of Boston Scientific in a research note on Wednesday, January 15th. Goldman Sachs Group began coverage on Boston Scientific in a research note on Wednesday, February 12th. They issued a “neutral” rating and a $46.00 price objective on the stock. Canaccord Genuity reissued a “buy” rating and issued a $58.00 price objective on shares of Boston Scientific in a research note on Thursday, February 6th. Finally, Stephens reduced their price objective on Boston Scientific from $48.00 to $35.00 and set an “overweight” rating on the stock in a research note on Monday. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $47.61.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: What is intrinsic value?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.